These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29966295)

  • 1. Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes.
    Aliwarga T; Evangelista EA; Sotoodehnia N; Lemaitre RN; Totah RA
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.
    Xu M; Ju W; Hao H; Wang G; Li P
    Drug Metab Rev; 2013 Aug; 45(3):311-52. PubMed ID: 23865864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation.
    Aliwarga T; Dinh JC; Heyward S; Prasad B; Gharib SA; Lemaitre RN; Sotoodehnia N; Totah RA
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2J2
    Tao P; Jiang Y; Wang H; Gao G
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):932-941. PubMed ID: 34707002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control.
    Leow JWH; Chan ECY
    Pharmacol Ther; 2024 Jun; 258():108637. PubMed ID: 38521247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes.
    Leow JWH; Gu Y; Chan ECY
    Eur J Pharm Sci; 2023 Aug; 187():106475. PubMed ID: 37225005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.
    Leow JWH; Verma RK; Lim ABH; Fan H; Chan ECY
    Eur J Pharm Sci; 2021 Sep; 164():105889. PubMed ID: 34044117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2J2 metabolites, epoxyeicosatrienoic acids, attenuate Ang II-induced cardiac fibrotic response by targeting Gα
    He Z; Yang Y; Wen Z; Chen C; Xu X; Zhu Y; Wang Y; Wang DW
    J Lipid Res; 2017 Jul; 58(7):1338-1353. PubMed ID: 28554983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.
    Spiecker M; Darius H; Hankeln T; Soufi M; Sattler AM; Schaefer JR; Node K; Börgel J; Mügge A; Lindpaintner K; Huesing A; Maisch B; Zeldin DC; Liao JK
    Circulation; 2004 Oct; 110(15):2132-6. PubMed ID: 15466638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
    Nayeem MA; Geldenhuys WJ; Hanif A
    Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.
    Li R; Xu X; Chen C; Wang Y; Gruzdev A; Zeldin DC; Wang DW
    Am J Physiol Endocrinol Metab; 2015 Feb; 308(4):E270-82. PubMed ID: 25389363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
    Xu X; Zhang XA; Wang DW
    Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.
    Chen C; Wei X; Rao X; Wu J; Yang S; Chen F; Ma D; Zhou J; Dackor RT; Zeldin DC; Wang DW
    J Pharmacol Exp Ther; 2011 Feb; 336(2):344-55. PubMed ID: 21030485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling.
    Lai J; Chen C
    Front Physiol; 2021; 12():642470. PubMed ID: 33716791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the association between CYP2J2 inhibitors and QT prolongation: a literature review.
    Wiley AM; Yang J; Madhani R; Nath A; Totah RA
    Drug Metab Rev; 2024; 56(2):145-163. PubMed ID: 38478383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 Epoxygenase 2J2 Protects Against Lung Ischemia/Reperfusion Injury by Activating the P13K/Akt/GSK-3-β/NF-kB Signaling Pathway During Deep Hypothermic Low Flow in Mice.
    Yang Y; Wang J; Peng W; Shu Y; Mo X
    J Surg Res; 2020 Sep; 253():8-17. PubMed ID: 32305498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity.
    Evangelista EA; Lemaitre RN; Sotoodehnia N; Gharib SA; Totah RA
    Drug Metab Dispos; 2018 Apr; 46(4):380-386. PubMed ID: 29343610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2J2 and its metabolites (epoxyeicosatrienoic acids) attenuate cardiac hypertrophy by activating AMPKα2 and enhancing nuclear translocation of Akt1.
    Wang B; Zeng H; Wen Z; Chen C; Wang DW
    Aging Cell; 2016 Oct; 15(5):940-52. PubMed ID: 27416746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2.
    Kojima A; Nadai M; Murayama N; Yamazaki H; Katoh M
    Xenobiotica; 2022 Jul; 52(7):669-675. PubMed ID: 36251932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2J2 and EETs protect against pulmonary arterial hypertension with lung ischemia-reperfusion injury in vivo and in vitro.
    Ding Y; Tu P; Chen Y; Huang Y; Pan X; Chen W
    Respir Res; 2021 Nov; 22(1):291. PubMed ID: 34774051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.